Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 7/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | USP2 | O75604 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4816615 | 0.92 | CYP3A4 (0.55) | CYP3A4CYP1A2CYP2D6CYP2C9TSHR | |
| SCHEMBL4808335 | 0.84 | KDM4E (0.56) | CYP3A4CYP2D6CYP2C9TSHRALDH1A1 | |
| SCHEMBL4819242 | 0.75 | KDM4E (0.56) | CYP3A4CYP2D6CYP2C9TSHRALDH1A1 | |
| SCHEMBL4817568 | 0.73 | MEN1 (0.56) | CYP3A4CYP1A2CYP2D6TSHRALDH1A1 | |
| SCHEMBL4821094 | 0.73 | CHKA (0.49) | PARP1 | |
| SCHEMBL4816896 | 0.73 | KDR (0.68) | CYP3A4 | |
| SCHEMBL4819958 | 0.73 | KCNJ1 (0.46) | ALDH1A1MEN1KMT2A | |
| SCHEMBL4820676 | 0.72 | ALDH1A1 (0.49) | TSHRALDH1A1MEN1KMT2A | |
| SCHEMBL4818998 | 0.69 | SMN1; SMN2 (0.58) | TSHRALDH1A1KMT2APARP1 | |
| SCHEMBL4813914 | 0.69 | KDR (0.68) | CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1740579-B1 | TRICYCLIC PYRAZOLE KINASE INHIBITORS | ABBVIE INC (US) | 2015-08-19 | — | — | EP | disclosed |
| US-7468371-B2 | Tricyclic pyrazole kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | ABBVIE INC. | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | PRKDC, PRKACA, PIK3C3 | CYP3A4 1811/4885CYP1A2 2708/4885CYP2D6 2834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.